MYC and cancer: Nonetheless, many of the genetic alterations present in cancer uncouple MYC expression from the usual regulatory constraints, either by constitutive activation of signal transduction pathways [e.g., Neurogenic locus notch homolog protein 1 (Notch), Wingless-related integration site (Wnt) and receptor tyrosine kinases (TKs)], or direct alterations of MYC, such as point mutations leading to protein stabilization, amplifications or translocations[18,19].